These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 22517820)

  • 1. Targeting triple-negative breast cancer: optimising therapeutic outcomes.
    Gelmon K; Dent R; Mackey JR; Laing K; McLeod D; Verma S
    Ann Oncol; 2012 Sep; 23(9):2223-2234. PubMed ID: 22517820
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characteristics of triple-negative breast cancer.
    de Ruijter TC; Veeck J; de Hoon JP; van Engeland M; Tjan-Heijnen VC
    J Cancer Res Clin Oncol; 2011 Feb; 137(2):183-92. PubMed ID: 21069385
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systemic treatment strategies for triple-negative breast cancer.
    Yadav BS; Sharma SC; Chanana P; Jhamb S
    World J Clin Oncol; 2014 May; 5(2):125-33. PubMed ID: 24829859
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emerging targeted therapies in triple-negative breast cancer.
    Crown J; O'Shaughnessy J; Gullo G
    Ann Oncol; 2012 Aug; 23 Suppl 6():vi56-65. PubMed ID: 23012305
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecularly targeted therapies for metastatic triple-negative breast cancer.
    Bayraktar S; Glück S
    Breast Cancer Res Treat; 2013 Feb; 138(1):21-35. PubMed ID: 23358903
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Triple-negative breast cancer and poly(ADP-ribose) polymerase inhibitors.
    Park Y; Moriyama A; Kitahara T; Yoshida Y; Urita T; Kato R
    Anticancer Agents Med Chem; 2012 Jul; 12(6):672-7. PubMed ID: 22263793
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Using multiple targeted therapies in oncology: considerations for use, and progress to date in breast cancer.
    Kelly CM; Buzdar AU
    Drugs; 2013 May; 73(6):505-15. PubMed ID: 23605692
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential anti-proliferative activities of poly(ADP-ribose) polymerase (PARP) inhibitors in triple-negative breast cancer cells.
    Chuang HC; Kapuriya N; Kulp SK; Chen CS; Shapiro CL
    Breast Cancer Res Treat; 2012 Jul; 134(2):649-59. PubMed ID: 22678161
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic strategies for triple-negative breast cancer.
    Tan AR; Swain SM
    Cancer J; 2008; 14(6):343-51. PubMed ID: 19060597
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relapsed triple-negative breast cancer: challenges and treatment strategies.
    Guarneri V; Dieci MV; Conte P
    Drugs; 2013 Aug; 73(12):1257-65. PubMed ID: 23842749
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Promising therapeutic options in triple-negative breast cancer.
    Bilici A; Arslan C; Altundag K
    J BUON; 2012; 17(2):209-22. PubMed ID: 22740196
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Triple-negative breast cancer: advancements in characterization and treatment approach.
    Hurvitz S; Mead M
    Curr Opin Obstet Gynecol; 2016 Feb; 28(1):59-69. PubMed ID: 26694831
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of triple negative breast cancer.
    Oakman C; Viale G; Di Leo A
    Breast; 2010 Oct; 19(5):312-21. PubMed ID: 20382530
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug target strategies in breast cancer treatment: recent developments.
    Mayank ; Jaitak V
    Anticancer Agents Med Chem; 2014; 14(10):1414-27. PubMed ID: 24712325
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Triple-negative breast cancer--current status and future directions.
    Gluz O; Liedtke C; Gottschalk N; Pusztai L; Nitz U; Harbeck N
    Ann Oncol; 2009 Dec; 20(12):1913-27. PubMed ID: 19901010
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Triple-negative breast cancer: current state of the art.
    Rastelli F; Biancanelli S; Falzetta A; Martignetti A; Casi C; Bascioni R; Giustini L; Crispino S
    Tumori; 2010; 96(6):875-88. PubMed ID: 21388048
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Updates in the treatment of basal/triple-negative breast cancer.
    Shastry M; Yardley DA
    Curr Opin Obstet Gynecol; 2013 Feb; 25(1):40-8. PubMed ID: 23222093
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthetic lethal interactions between EGFR and PARP inhibition in human triple negative breast cancer cells.
    Nowsheen S; Cooper T; Stanley JA; Yang ES
    PLoS One; 2012; 7(10):e46614. PubMed ID: 23071597
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting basal-like breast cancers.
    Dey N; Smith BR; Leyland-Jones B
    Curr Drug Targets; 2012 Nov; 13(12):1510-24. PubMed ID: 22974394
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proteomics as a Guide for Personalized Adjuvant Chemotherapy in Patients with Early Breast Cancer.
    Lumachi F; Chiara GB; Foltran L; Basso SM
    Cancer Genomics Proteomics; 2015; 12(6):385-90. PubMed ID: 26543084
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.